CN Patent

CN102552177B — 重组人脑钠肽的冻干制剂及其制备方法

Assigned to Nuodikang Pharmaceutical Industry Co., Ltd., Tibet · Expires 2013-04-10 · 13y expired

What this patent protects

本发明公开了一种重组人脑钠肽冻干制剂，它是由如下重量配比的原料药及辅料制备而成：重组人脑钠肽0.5份，缓冲液体系0.2-20份、赋形剂1-20份、NaCl 1-20份。本发明还公开了重组人脑钠肽冻干制剂的制备方法。本发明通过对辅料的优选，使得重组人脑钠肽具有良好的稳定性，保证了药物的有效性和安全性。

USPTO Abstract

本发明公开了一种重组人脑钠肽冻干制剂，它是由如下重量配比的原料药及辅料制备而成：重组人脑钠肽0.5份，缓冲液体系0.2-20份、赋形剂1-20份、NaCl 1-20份。本发明还公开了重组人脑钠肽冻干制剂的制备方法。本发明通过对辅料的优选，使得重组人脑钠肽具有良好的稳定性，保证了药物的有效性和安全性。

Drugs covered by this patent

Patent Metadata

Patent number
CN102552177B
Jurisdiction
CN
Classification
—
Expires
2013-04-10
Drug substance claim
No
Drug product claim
No
Assignee
Nuodikang Pharmaceutical Industry Co., Ltd., Tibet
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.